home.social

#nvo — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #nvo, aggregated by home.social.

  1. Top global stories this week: ASML, Tesco, Taiwan Semiconductor among notable names

    #stoxx #ukx #lvmhf #lvmuy #asml #nvo #openai #tscdy #shcomp #deepseek #tsm

    Origin | Interest | Match
  2. Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

    Last Updated: Feb. 11, 2026 at 8:59 a.m. ETFirst Published: Feb. 10, 2026 at 3:48 p.m. ET Patients are thrilled…
    #NewsBeep #News #Medication #CA #Canada #consumer-affairs #corporate #Corporate/IndustrialNews #ELILILLY&CO #Health #HealthCare #Hims #Hims&HersHealthInc #industrialnews #LLY #Manufacturing #NovoNordiskA/SADR #NVO #pharmaceuticals
    newsbeep.com/ca/469518/

  3. Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

    Published: Feb. 10, 2026 at 3:48 p.m. ET Patients are thrilled that there’s finally a GLP-1 pill, but swallo…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication ##ConsumerAffairs #corporate #Corporate/IndustrialNews #ELILILLY&CO #Health #Healthcare #hims #Hims&HersHealthInc #industrialnews #LLY #manufacturing #NovoNordiskA/SADR #NVO #Pharmaceuticals
    newsbeep.com/us/461304/

  4. Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

    Published: Feb. 10, 2026 at 3:48 p.m. ET Patients are thrilled that there’s finally a GLP-1 pill, but swallo…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication ##ConsumerAffairs #corporate #Corporate/IndustrialNews #ELILILLY&CO #Health #Healthcare #hims #Hims&HersHealthInc #industrialnews #LLY #manufacturing #NovoNordiskA/SADR #NVO #Pharmaceuticals
    newsbeep.com/us/461304/

  5. FCF Conversion 💰

    Does #EBIT turn into free cash flow?

    ➡️ #NVO and #RMS convert ~70%.
    ➡️ #STR and #DSY convert over 100%, a warning sign (!) that needs investigation.

    None get a clean pass here!

    (3/5)

  6. Allocation Ratios 🔄

    How do they spend their cash, reinvest or buy back shares?

    ➡️ #NVO, #STR and #RMS show inconsistent reinvestment patterns.
    ➡️ #DSY leans heavily toward buybacks.

    Mixed signals across the board!

    (2/5)

  7. Allocation Ratios 🔄

    How do they spend their cash, reinvest or buy back shares?

    ➡️ #NVO, #STR and #RMS show inconsistent reinvestment patterns.
    ➡️ #DSY leans heavily toward buybacks.

    Mixed signals across the board!

    (2/5)

  8. Cash Is Truth 💵

    #Revenue tells a story, but cash delivers the reality check.

    Today’s sneak peek looks at how #NVO, #STR, #RMS and #DSY actually turn profits into cash.

    Let’s dig in!

    (1/5)

    #ValueInvesting #Investing #Finance #FinancialAnalysis #Markets

  9. Cash Is Truth 💵

    #Revenue tells a story, but cash delivers the reality check.

    Today’s sneak peek looks at how #NVO, #STR, #RMS and #DSY actually turn profits into cash.

    Let’s dig in!

    (1/5)

    #ValueInvesting #Investing #Finance #FinancialAnalysis #Markets

  10. Cash Is Truth 💵

    #Revenue tells a story, but cash delivers the reality check.

    Today’s sneak peek looks at how #NVO, #STR, #RMS and #DSY actually turn profits into cash.

    Let’s dig in!

    (1/5)

    #ValueInvesting #Investing #Finance #FinancialAnalysis #Markets

  11. Cash Is Truth 💵

    #Revenue tells a story, but cash delivers the reality check.

    Today’s sneak peek looks at how #NVO, #STR, #RMS and #DSY actually turn profits into cash.

    Let’s dig in!

    (1/5)

    #ValueInvesting #Investing #Finance #FinancialAnalysis #Markets

  12. Working Capital Quality 📊

    Does #revenue convert to #cash?

    ☑️ #STR, #RMS and #DSY pass.
    ☑️ #NVO gets a red flag, but not for the reason you think.

    More in the full Validation series!

    (5/5)

    #FindItFinancials #TheBarnBlog #NotInvestmentAdvice

  13. Net Debt / OCF 💰

    How exposed are they to #debt?

    🟢 Below 2.0x = strong
    🟡 2–4x = manageable
    🔴 Above 4x = red flag

    #NVO, #STR, #RMS and #DSY all land safely below 2.0x -> green light!

    (2/5)

  14. Net Debt / OCF 💰

    How exposed are they to #debt?

    🟢 Below 2.0x = strong
    🟡 2–4x = manageable
    🔴 Above 4x = red flag

    #NVO, #STR, #RMS and #DSY all land safely below 2.0x -> green light!

    (2/5)

  15. Validation Sneak Peek 🔎

    This week we start the balance-sheet reality check in #TheBarnBlog

    Four cornerstone metrics reveal how resilient our screener finalists really are.

    Let’s see what #NVO, #STR, #RMS and #DSY look like!

    (1/5)

    #FindItFinancials #ValueInvesting #FinancialAnalysis #Markets

  16. Validation Sneak Peek 🔎

    This week we start the balance-sheet reality check in #TheBarnBlog

    Four cornerstone metrics reveal how resilient our screener finalists really are.

    Let’s see what #NVO, #STR, #RMS and #DSY look like!

    (1/5)

    #FindItFinancials #ValueInvesting #FinancialAnalysis #Markets

  17. Validation Sneak Peek 🔎

    This week we start the balance-sheet reality check in #TheBarnBlog

    Four cornerstone metrics reveal how resilient our screener finalists really are.

    Let’s see what #NVO, #STR, #RMS and #DSY look like!

    (1/5)

    #FindItFinancials #ValueInvesting #FinancialAnalysis #Markets

  18. Validation Sneak Peek 🔎

    This week we start the balance-sheet reality check in #TheBarnBlog

    Four cornerstone metrics reveal how resilient our screener finalists really are.

    Let’s see what #NVO, #STR, #RMS and #DSY look like!

    (1/5)

    #FindItFinancials #ValueInvesting #FinancialAnalysis #Markets

  19. ​$11.7B ICFR GAP. Pothole? No. Structural failure.

    ​Novo Nordisk’s manufacturing scale-up strategy is built on a #CriticalRisk: The Catalent acquisition systems are excluded from ICFR oversight.

    ​They solved for supply. They failed on data integrity.

    ​A hostile data strategist targets this control gap.

    ​Find your competitor's fatal flaw: Data-Backed Competitive Insight. $6k.

    #DataGovernance #MAndA #NVO #ShaolinDataScience

  20. ​$11.7B ICFR GAP. Pothole? No. Structural failure.

    ​Novo Nordisk’s manufacturing scale-up strategy is built on a #CriticalRisk: The Catalent acquisition systems are excluded from ICFR oversight.

    ​They solved for supply. They failed on data integrity.

    ​A hostile data strategist targets this control gap.

    ​Find your competitor's fatal flaw: Data-Backed Competitive Insight. $6k.

    #DataGovernance #MAndA #NVO #ShaolinDataScience

  21. Är börsen öppen idag?

    Ja det är den. Kul då kan vi handla aktier igen. Novo Nordisk sticker uppåt efter sin kraftiga dipp.
    Köpte ni i dippen?

    #börs #aktie #NovoNordisk #nvo

  22. Idag handlades Novo Nordisk till vrakpris. Bra köptillfälle så här inför jul.

    Mellandagsrean började tidigt skulle man kunna säga. En rejäl prissänkning på 20%.

    #aktier #mellandagsrea #börs #nvo

  23. “Nevalstiskās organizācijas nav dienests”
    – Inese Vaivare stāsta par biedrību iesaisti civilajā aizsardzībā Ministru kabineta Zaļajā zālē.
    #nvo

  24. The financial world has become a high-stakes poker table where knowing your own hand isn't enough. You need insight into the cards others hold and how they perceive their value.

    A company might announce positive news—say, better-than-expected earnings or a promising new product line—yet its stock could still drop if traders had already anticipated the good news and bought into the stock in advance, driving up the price. Like #NVO after last earnings.

  25. Expectations are high, with analysts predicting that by 2029, combined sales for Zepbound and Mounjaro could surpass $40 billion, with some projections reaching up to $100 billion annually. However, current supply constraints are a significant concern, potentially impacting short-term sales. Both Eli Lilly and its competitor, Novo Nordisk, are struggling to keep up with the overwhelming demand for their weight-loss injections, making the drugs difficult for some patients to obtain. #LLY #NVO

  26. For the fourth quarter, Novo Nordisk surpassed Wall Street's expectations, reporting earnings of $0.71 per share, a 7.6% beat. Net sales for the quarter jumped 37% year-over-year to $9.5 billion, driven by strong sales in Diabetes and Obesity Care. Despite sharp increases in GLP-1 product sales, there was a slight offset by declines in insulin and rare disease sales. #GLP1 #NVO #LLY

  27. A standout in this flourishing market is Novo Nordisk (#NVO), which has seen its shares increase by about 22% year-to-date, outperforming the broader market. This surge is partly due to the recent FDA approval expansion of its weight-loss medication, Wegovy, now also approved for reducing cardiovascular risk in overweight patients. This approval potentially opens up Wegovy to an expanded market of around 3.6 million Medicare-eligible patients, according to a Kaiser Family Foundation analysis.

  28. The pharmaceutical sector is poised for significant expansion, with projections indicating a growth to approximately $2.8 trillion by 2033, fueled by a compound annual growth rate of 6.2%. This growth is driven by factors such as an aging population, increased healthcare expenditures, advancements in biotechnology, and the rising prevalence of lifestyle-related diseases. #NVO

  29. The increasing popularity of GLP-1 drugs like Novo Nordisk's Wegvoy (semaglutide) and Eli Lilly's Zepbound (tirzepatide), famed for their weight loss benefits, is reshaping consumer behavior in unexpected ways, according to a recent Morgan Stanley survey. Here’s a deep dive into the effects these drugs are having on spending habits, particularly within the food industry. #GLP1 #LLY #NVO

  30. Ali nova e-osebna izkaznica dela tudi na Linux operacijsskem sistemu? Trenutno še ne 😒️
    Je pa mreža NVO-VID poslala povpraševanje in zahtevo na Ministrstvo za digitalno preobrazbo ⬇️
    na-prostem.si/clanek/pismo-min

    #linux #NVO #dostopnost

  31. Je kdo član nevladne organizacije in bi šaltal na odprtokodne programe? Nudimo brezplačna praktična usposabljanja za uporabo najbolj popularnih in preverjenih odprtokodnih programov ⬇️
    na-prostem.si/clanek/prakticna
    #opensource #floss #education #ngo #NVO #usposabljanje #delavnice

  32. Naslednje c| srečanje bo v ponedeljek, 3. aprila 2023 ob 18h, v Računalniškem muzeju / @muzej

    Kristijan Tkalec / @lapor bo predstavil kakšne potrebe imajo nevladne organizacije pri nas po odprto-kodnih rešitvah in storitvah.

    Kot vedno, bo potem sledila neformalna debata in druženje. Mogoče pohekamo sistem, nč ne oblubm ;)

    dogodki.kompot.si/events/8520a

    glej @kiberpipa_cyberpipe 🧵 in se pofočkaj ☝️

    #Kiberpipa #Cyberpipe #FOSS #OdprtaKoda #NVO

  33. Naslednje c| srečanje bo v ponedeljek, 3. aprila 2023 ob 18h, v Računalniškem muzeju / @muzej

    Kristijan Tkalec / @lapor bo predstavil kakšne potrebe imajo nevladne organizacije pri nas po odprto-kodnih rešitvah in storitvah.

    Kot vedno, bo potem sledila neformalna debata in druženje. Mogoče pohekamo sistem, nč ne oblubm ;)

    dogodki.kompot.si/events/8520a

    glej @kiberpipa_cyberpipe 🧵 in se pofočkaj ☝️

    #Kiberpipa #Cyberpipe #FOSS #OdprtaKoda #NVO

  34. V okviru projekta Na-prostem.si so zasnovali deset paketov usposabljanj za uporabo odprtokodnih programov in storitev, s poudarkom na tistih, ki so namenjeni dejavnostim za tekoče delovanje nevladnih organizacij in njihovih uporabnikov.
    V spodnjem članku preverite, katera usposabljanja pripravljajo mentorji.
    na-prostem.si/clanek/tutoriali

    #OdprtaKoda #ProstoProgramje #izobraževanje #usposabljanje #NVO #NevladneOrganizacije #digitalizacija #DigitalnaPreobrazba

  35. #NVO na področju zdravja: ne zamudite #razpisa #EU4Health za:

    💪 zdravstvene pismenosti & promocije zdravja,
    💪 optimizacije dejavnosti #healthcare,
    💪 komunikacije s pacienti,
    💪 sodelovanja z medn. org. in civilno družbo.

    Rok za prijavo: 31.1. 👇
    hadea.ec.europa.eu/news/new-eu

    🐦🔗: n.respublicae.eu/EKvSloveniji/

  36. "Lēmumu tapšanā Latvijā ir labi sadzirdami turīgi spēlētāji ar spēcīgām ietekmes svirām. Tikmēr pilsoniskās organizācijas nereti tiek nostādītas neērtu protestētāju pozīcijā vai uzklausītas tikai tehniska līmeņa nišās."

    #prioritātes #NVO

    delfi.lv/news/versijas/elina-p